NCT01965379

Brief Summary

Hyperphosphatemia is related to the increase in morbidity and mortality. There is greater risk for cardiovascular disease, atherosclerotic disease, secondary hyperparathyroidism, and bone disease . The serum phosphorus level can be controlled by a combination of factors, such as: reduction of ingestion, reduction of intestinal absorption with chelating agents and increase in elimination by dialysis. The purpose of this study is to evaluate the effect of dietary intervention consisting of the restriction of industrialized foods with phosphorus additives in chronic kidney disease patients treated with hemodialysis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
140

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2012

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2012

Completed
1.8 years until next milestone

First Submitted

Initial submission to the registry

October 9, 2013

Completed
9 days until next milestone

First Posted

Study publicly available on registry

October 18, 2013

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2013

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2014

Completed
Last Updated

March 10, 2015

Status Verified

March 1, 2015

Enrollment Period

1.9 years

First QC Date

October 9, 2013

Last Update Submit

March 9, 2015

Conditions

Keywords

DialysisPhosphorusDiet

Outcome Measures

Primary Outcomes (1)

  • Change the serum levels of phosphorus to acceptable levels ( under 5.5 mg per dL)

    90 days

Secondary Outcomes (5)

  • Protein intake at baseline and final.

    90 days

  • Energy intake at baseline and at the final.

    90 days

  • Triceps skinfold at baseline and final.

    90 days

  • Body mass index at baseline and final

    90 days

  • Arm muscle area at baseline and final

    90 days

Study Arms (2)

Intervention

ACTIVE COMPARATOR

Restriction on food containing phosphorus additives.

Other: Restriction on food containing phosphorus additives

Control

PLACEBO COMPARATOR

Standard care.

Other: Standard care

Interventions

The substitution of foods containing phosphorus additives for others with the same nutritional value for each individual of the study.

Intervention

The control group mantained the usual renal diet oriented prior to the study with a booklet.

Control

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • males or female ≥ 18 years of age
  • Chronic kidney disease in stage 5, on hemodialysis for at least 6 months
  • Serum phosphorus (P) greater than 5.5 mg/dL persistent in 3 previous months
  • Preserved cognitive capacity and able to read and write
  • Signed informed written consent

You may not qualify if:

  • Use of enteral or parenteral therapy
  • Presence of physical or cognitive limitation
  • Malabsorption diseases.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculdade de Ciências Médicas da Santa Casa de São Paulo

São Paulo, São Paulo, 01221-020, Brazil

Location

MeSH Terms

Conditions

Kidney Failure, ChronicHyperphosphatemia

Interventions

Standard of Care

Condition Hierarchy (Ancestors)

Renal Insufficiency, ChronicRenal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsPhosphorus Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

Quality Indicators, Health CareQuality of Health CareHealth Services AdministrationHealth Care Quality, Access, and Evaluation

Study Officials

  • Yvoty AS Sens, PHD

    Faculdade de Ciências Médicas da Santa Casa de São Paulo

    STUDY CHAIR
  • Margareth LL Fornasari, RD

    Faculdade de Ciências Médicas da Santa Casa de São Paulo

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PHD student

Study Record Dates

First Submitted

October 9, 2013

First Posted

October 18, 2013

Study Start

January 1, 2012

Primary Completion

December 1, 2013

Study Completion

June 1, 2014

Last Updated

March 10, 2015

Record last verified: 2015-03

Locations